MedTrace Logo

Effects of Levosimendan in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy

NCT01188369 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-12-03

Study results available
· View outcomes & findings →

Summary

This is a clinical, randomised, double-blinded study in which patients eligible for aortic valve replacement are enrolled. Patients receive infusion of either levosimendan or placebo 4 hours prior to surgery and until the end of surgery.

Conditions

  • Diastolic Dysfunction
  • Left Ventricular Hypertrophy

Interventions

DRUG

levosimendan

Intravenous infusion, 0,1ug/kg/min, duration 4 hours prior to operation and until the end of operation.

DRUG

placebo drug

Intravenous infusion, colour identical to levosimendan

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Peter Juhl-Olsen, M.D. · Department of Anaesthesiology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • Denmark

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01188369 on ClinicalTrials.gov